Novel plasma therapy for covid-19: A Perspective

Chandani Kamble; Sharad Kamble; Pragati Pandit

doi:10.37591/rrjooh.v10i3.2724

Abstract

Coronavirus disease (COVID-19) is an induced disease caused by the coronavirus-19 that causes acute respiratory syndrome (SARS COVID-19). In the month of December 2019, the first case was recorded in Wuhan, China. No specific medications have yet been approved for their treatment; convalescent plasma therapy is projected to boost the survival rate. Early in the twentieth century, convalescent plasma therapy was developed. Convalescent plasma therapy is widely utilized around the world, and it has proven to be effective in saving the lives of COVID-19 patients. Convalescent plasma containing antibodies capable of neutralizing SARS-CoV-2 has shown potential in preventing viral replication and relieving patients' clinical symptoms in preliminary investigations. To definitively elucidate the safety and efficacy of this blood component in COVID-19, the findings of numerous ongoing randomized controlled trials are eagerly awaited. The current evidence from the literature on the treatment of serve COVID-19 with convalescent plasma is summarized in this narrative review.

Abstract

Keywords